7月8日 - ** ProKidney PROK.O股价盘前上涨62.4%至1.25美分
** 该公司称其药物rilparencel在中期试验中显示慢性肾脏病和糖尿病患者肾功能下降的情况有所改善
** PROK 即将与美国食品药品管理局举行会议，以确定该药物计划后期试验的方法
** 截至上次收盘，股价累计下跌 64
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.